Posting strong pharma sales but weakness in academia and government, Waters matched analysts' average EPS estimate for the quarter but fell short on revenues.
While most firms launched new mass spec systems, the larger focus was on developing and implementing the larger workflows surrounding these instruments.
Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.
Driven by strong pharma demand, the company posted first quarter revenues of $475.2 million, beating the average Wall Street estimate of $472.2 million.
